Cyclacel Pharmaceuticals

(NASDAQ: CYCC)
Healthcare  |  Biotechnology
0.37 0.0015 0.4%
Stock Price | Oct. 18, 2019, 2:42 p.m.
0 Followers
Bid: 0.0
Ask: 0.0
Prev. Close: 0.3706
52 Week Low: 0.2813
52 Week High: 1.7
PE Ratio: 0.0
Dividend Yield: 0.0%

Company Summary

Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company which develops targeted medicines for cancer and other proliferative diseases. It develops several families of anticancer drugs that act on the cell cycle, including nucleoside analogs, CDK (cyclin dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include CYC065 CDK inhibitor, Sapacitabine and seliciclib, CYC682, CYC140 PLK inhibitor, and CYC202. The company earns the majority of its revenue from the United Kingdom.

Read more Read less

Recently Viewed Tickers

Premium Stock Watchlist 4/15/2015

4 years ago